Company Overview of IBC Pharmaceuticals, L.L.C.
IBC Pharmaceuticals, L.L.C. focuses on the development of novel cancer therapeutics using proprietary pre-targeting, bi-specific antibody technologies developed at Immunotech in Marseille, France. Immunotech was later purchased by Coulter Corporation, which subsequently became part of Beckman Coulter. IBC's first product candidate is currently being evaluated in Phase I/II clinical trials in France for the therapy of tumors producing carcinoembryonic antigen, or CEA. In May 2002, Immunomedics, Inc. (Nasdaq: IMMU) acquired the remaining 43% interest in IBC Pharmaceuticals, L.L.C. from Beckman Coulter, Inc.
Morris Plains, NJ
Key Executives for IBC Pharmaceuticals, L.L.C.
IBC Pharmaceuticals, L.L.C. does not have any Key Executives recorded.
Similar Private Companies By Industry
|Criterium, Inc.||United States|
|Chakshu Research, Inc.||United States|
|Physicians Clinical Research Solutions, Inc.||United States|
|Danube Pharmaceuticals, Inc.||United States|
|Pharmaron, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Post a JobJobs
- Tampa, FL | Bristol-Myers SquibbPosted: Nov 13
- Augusta, GA | AstraZenecaPosted: Dec 19
- Deerfield, IL | Takeda Pharmaceuticals North AmericaPosted: Oct 22
- Bridgewater, NJ | InformaticaPosted: Dec 11
Sponsored Financial Commentaries
To contact IBC Pharmaceuticals, L.L.C., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.